Hematopoiesis News Volume 14.36 | Sep 12 2023

    By
    Jamie Kang
    -
    0
    30







    2023-09-12 | HN 14.36


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.36 – 12 September, 2023
    TOP STORY

    Notch and Retinoic Acid Signals Regulate Macrophage Formation from Endocardium Downstream of Nkx2-5

    In vivo and ex vivo analyses validated that the Nkx2-5-Notch axis was essential for the generation of both hemogenic and cushion endocardial cells, and the suppression of retinoic acid signaling via Dhrs3 expression played important roles in further differentiation into macrophages.
    [Nature Communications]

    Full Article
    The STEMdiffâ„¢ Monocyte Kit generates millions of monocytes ready for downstream assays or further development into macrophages or dendritic cells.
    PUBLICATIONSRanked by the impact factor of the journal

    ZAKα/P38 Kinase Signaling Pathway Regulates Hematopoiesis by Activating the NLRP1 Inflammasome

    Investigators reported that genetic inhibition of Nlrp1 resulted in a reduced number of neutrophils and increased erythrocyte counts in zebrafish larvae.
    [EMBO Molecular Medicine]

    Full ArticleGraphical Abstract

    FBXO21 Mediated Degradation of p85α Regulates Proliferation and Survival of Acute Myeloid Leukemia

    Scientists revealed that the ubiquitin E3 ligase, FBXO21, played a critical role in regulating AML pathogenesis, specifically through alterations in PI3K via regulation of p85α protein stability.
    [Leukemia]

    Full Article

    CAR Virus Receptor Mediates Erythroid Differentiation and Migration and Is Downregulated in MDS

    Investigators screened for genes that were expressed abnormally in erythroid progenitor cells (EP) and contributed to the pathogenesis of myelodysplastic syndromes (MDS). They found that the Coxsackie-Adenovirus receptor was markedly downregulated in CD45low/CD105+ EP in MDS patients.
    [Leukemia]

    Abstract

    PLK1 as a Cooperating Partner for BCL2-Mediated Antiapoptotic Program in Leukemia

    Researchers developed a drug sensitivity prediction model utilizing a deep tabular learning algorithm for the assessment of venetoclax sensitivity in T cell acute lymphoblastic leukemia patient samples.
    [Blood Cancer Journal]

    Full ArticleGraphical Abstract

    Polyclonal Immunoglobulin Recovery in Patients with Newly Diagnosed Myeloma Receiving Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation with Either Carfilzomib, Lenalidomide and Dexamethasone or Lenalidomide Alone: Subanalysis of the Randomized Phase III ATLAS Trial

    Investigators performed a longitudinal analysis of polyclonal immunoglobulin concentrations and unique B cell sequences in patients enrolled in the Phase III ATLAS trial that randomized 180 subjects to either carfilzomib, lenalidomide, dexamethasone, or lenalidomide maintenance.
    [British Journal Of Haematology]

    Full Article

    Allogeneic Hematopoietic Cell Transplantation in Patients with CALR-Mutated Myelofibrosis: A Study of the Chronic Malignancies Working Party of EBMT

    Scientists analyzed outcomes of 346 CALR-mutated myelofibrosis patients who underwent allogeneic hematopoietic cell transplantation in 123 EBMT centers between 2005 and 2019.
    [Bone Marrow Transplantation]

    Abstract

    Randomized Phase-III Study of Low-Dose Cytarabine and Etoposide + /− All-Trans Retinoic Acid in Older Unfit Patients with NPM1-Mutated Acute Myeloid Leukemia

    Investigators evaluated the impact of all-trans retinoic acid in combination with non-intensive chemotherapy in older unfit patients (> 60 years) with newly diagnosed NPM1-mutated acute myeloid leukemia.
    [Scientific Reports]

    Full Article

    Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

    Researchers conducted a Phase I/II multicenter study to evaluate the safety, pharmacokinetics, and activity of azacitidine in children with relapsed myelodysplastic syndrome and juvenile myelomonocytic leukemia (MDS/JMML) prior to the second hematopoietic stem cell transplantation.
    [Pediatric Drugs]

    Abstract
    Animal Origin-Free cGMP HSPC Expansion Media
    REVIEWS

    Hemostasis without Clot Formation – How Platelets Guard the Vasculature in Inflammation, Infection, and Malignancy

    The authors summarize previously recognized and more recent studies that have elucidated how anucleate, small platelets manage to maintain vascular integrity when faced with challenges of infection, sterile inflammation, and even malignancy.
    [Blood]

    Abstract
    INDUSTRY AND POLICY NEWS

    Foghorn Therapeutics Announces First Patient Dosed in Phase I Combination Study of FHD-286 for Relapsed and/or Refractory AML

    Foghorn® Therapeutics, Inc. announced the first patient has been dosed in the Phase I study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML.
    [Foghorn® Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    Immunity and Aging

    October 1 – 4, 2023
    Whistler, British Columbia, Canada

    > See All Events

    JOB OPPORTUNITIES

    Investigator – Hematopoiesis

    Versiti Blood Research Institute, – Wisconsin Rapids, Wisconsin, United States

    Laboratory Research Scientist – Human Normal and Leukemic Stem Cells

    Francis Crick Institute – London, England, United Kingdom

    PhD Scholarship – Single-Cell Proteomics and AML

    Technical University of Denmark – Kongens Lyngby, Denmark

    Faculty Positions – Cancer Metastasis

    The Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States

    Research Fellowship – Biochemical Mechanisms of Blood Coagulation

    Center for Biologics Evaluation and Research – Silver Spring, Maryland, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter